Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 1929-1939

  Hardwick, Nicola ^a   Ledermann, Jonathan A ^b,c   Aitkens, Egla ^c   Chain, Benny ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Dendritic cell therapy; Hypochlorous acid; Immunotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ANTIGEN; DENDRITIC CELL VACCINE; NEUTRALIZING ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL ACTIVATION; CELL DIFFERENTIATION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL STIMULATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; LYMPHOCYTE FUNCTION; MESOTHELIUM; MONOCYTE; OVARY CANCER; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; MONOCYTES; OVARIAN NEOPLASMS; POLY I-C; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84870987755     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1252-2     Document Type: Article

References (43)

1. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G (2011) Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 30: 141-151
2. Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222:101-116
3. Cheever MA, Higano C (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA approved therapeutic cancer vaccine. Clin Cancer Res 17:3520-3526
4. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX et al (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12:869-877
5. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T (2002) Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51:45-52
6. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108
7. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA et al (2009) A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 15:5937-5944
8. Marcinkiewicz J (1997) Neutrophil chloramines: missing links between innate and acquired immunity. Immunol Today 18: 577-580
9. Chiang CL, Ledermann JA, Rad AN, Katz DR, Chain BM (2006) Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 55:1384-1395
10. Prokopowicz ZM, Arce F, Biedron R, Chiang CL, Ciszek M, Katz DR et al (2010) Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 184:824-835
11. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM (2008) Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 14:4898-4907
12. Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M et al (2011) Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigenspecific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 63:84-95
13. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R et al (2005) HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 11:67-72
14. Sheu JJ, Shih Ie M (2007) Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol 17: 436-443
15. Jung YW, Kim YT, Kim SW, Kim S, Kim JH, Cho NH et al (2009) Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Reprod Sci 16:1103-1111
16. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE et al (2011) Induction of CD8 ? T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330-336
17. Rolland P, Deen S, Scott I, Durrant L, Spendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13:3591-3596
18. Leffers N, Lambeck AJ, de Graeff P, Bijlsma AY, Daemen T, van der Zee AG et al (2008) Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol 110:365-373
19. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A et al (2010) Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early andadvanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 31:375-383
20. Giuntoli R L II, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE et al (2009) Ovarian cancer-Associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875-2884
21. Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ et al (2010) Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS ONE 5:e15625
22. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183
23. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ et al (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123
24. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Zhang H et al (2004) TGF-beta induces Foxp3 ? T-regulatory cells from CD4 ? CD25 -precursors. Am J Transplant 4:1614-1627
25. Gregg RK, Jain R, Schoenleber SJ, Divekar R, Bell JJ, Lee HH et al (2004) A sudden decline in active membrane-bound TGFbeta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 173:7308-7316
26. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast R C Jr et al (2001) Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 80:245-253
27. Knippertz I, Hesse A, Schunder T, Kampgen E, Brenner MK, Schuler G et al (2009) Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFNgamma. J Immunother 32:524-538
28. Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK (2004) Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res 116:24-31
29. Osada T, Nagawa H, Takahashi T, Tsuno NH, Kitayama J, Shibata Y (2002) Dendritic cells cultured in anti-CD40 antibodyimmobilized plates elicit a highly efficient peptide-specific T-cell response. J Immunother 25:176-184
30. Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C et al (2009) A clinical grade poly I:C-Analogue (Ampligen) promotes optimal DC maturation and Th1-Type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27: 107-115
31. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R (2010) Immature immunosuppressive CD14 ? HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335-4345
32. Weng D, Song B, Durfee J, Sugiyama V, Wu Z, Koido S et al (2001) (2010) Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer 129:1990
33. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW et al (2007) Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol 148:136-145
34. Sun L, Kong B, Sheng X, Sheu JJ, Shih Ie M (2010) Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. Biochem Biophys Res Commun 394:633-638
35. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M et al (2009) Induction of human tumor-Associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer 115:800-811
36. Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C et al (2005) (2005) Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 99:462-471
37. Gritzapis AD, Perez SA, Baxevanis CN, Papamichail M (2005) Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo. Br J Cancer 92:72-79
38. Bellavance EC, Kohlhapp FJ, Zloza A, O'Sullivan JA, McCracken J, Jagoda MC et al (2011) Development of Tumor-Infiltrating CD8 ? T Cell Memory Precursor Effector Cells and Antimelanoma Memory Responses Are the Result of Vaccination and TGF-{beta} Blockade during the Perioperative Period of Tumor Resection. J Immunol 186:3309-3316
39. Nagaraj NS, Datta PK (2010) Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 19:77-91
40. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H et al (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79:1236-1243
41. Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I et al (2003) Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 74:1094-1101
42. Monti P, Leone BE, Zerbi A, Balzano G, Cainarca S, Sordi V et al (2004) Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 172:7341-7349
43. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P et al (2005) Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174: 3032-3040